Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Orally to Healthy Subjects.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Danegaptide (Primary)
- Indications Arrhythmias
- Focus Adverse reactions
- Sponsors Wyeth
- 28 Jan 2009 Actual initiation date (Feb 2009) added as reported by ClinicalTrials.gov.
- 28 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 Jan 2009 New trial record.